New combo tackles Tough-to-Treat colorectal cancer
NCT ID NCT03711058
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—copanlisib and nivolumab—in 48 adults with advanced solid tumors, specifically a type of colorectal cancer called MSS that usually doesn't respond to immunotherapy alone. The goal was to see if the combination could shrink tumors and to find the safest dose. The study is now complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Copanlisib and nivolumab
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced MSS colorectal cancer, a type that typically does not respond to immunotherapy alone.
- What could go wrong
- This was an early-phase trial with only 48 participants, so results may not apply to everyone. The drugs can cause serious side effects like lung inflammation and liver problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSATELLITE STABLE (MSS) COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.